StockData
Liquidia Corp logo

Liquidia Corp (LQDA) stock

LQDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3075% above fair value
$56.73+0.36 (+0.64%)

Close on Nov 17, 2026Market cap $5.08BP/E 40.8Yield –

Liquidia r&d expenses

Research and development expenses are spending on new products and technology.

Liquidia's R&D Expenses for the twelve months ending Jun 30, 2026 was $56.04M, up 35.5% year over year. For fiscal 2025 it was $39.28M, down 17.9% from the year before. The highest annual figure on record is $47.84M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$39.28M-17.9%
FY2024Dec 31, 2024$47.84M+10.6%
FY2023Dec 31, 2023$43.24M+122.5%
FY2022Dec 31, 2022$19.44M-5.3%
FY2021Dec 31, 2021$20.52M-36.3%
FY2020Dec 31, 2020$32.22M-20.4%
FY2019Dec 31, 2019$40.49M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.18M+185.4%
Q1 FY2026Mar 31, 2026$12.57M+80.5%
Q4 FY2025Dec 31, 2025$16.94M+2.8%
Q3 FY2025Sep 30, 2025$9.35M-21.4%
Q2 FY2025Jun 30, 2025$6.02M-36.1%
Q1 FY2025Mar 31, 2025$6.97M-30.7%
Q4 FY2024Dec 31, 2024$16.48M+28.4%
Q3 FY2024Sep 30, 2024$11.89M+59.8%
Q2 FY2024Jun 30, 2024$9.42M-46.8%
Q1 FY2024Mar 31, 2024$10.06M+90.5%
Q4 FY2023Dec 31, 2023$12.83M+157.8%
Q3 FY2023Sep 30, 2023$7.44M+64.9%
Q2 FY2023Jun 30, 2023$17.70M+239.0%
Q1 FY2023Mar 31, 2023$5.28M+11.6%
Q4 FY2022Dec 31, 2022$4.98M-7.5%
Q3 FY2022Sep 30, 2022$4.51M+0.6%
Q2 FY2022Jun 30, 2022$5.22M+13.6%
Q1 FY2022Mar 31, 2022$4.73M-21.9%
Q4 FY2021Dec 31, 2021$5.38M+2.5%
Q3 FY2021Sep 30, 2021$4.49M-41.4%
Q2 FY2021Jun 30, 2021$4.60M-45.9%
Q1 FY2021Mar 31, 2021$6.05M-44.1%
Q4 FY2020Dec 31, 2020$5.25M–
Q3 FY2020Sep 30, 2020$7.66M–
Q2 FY2020Jun 30, 2020$8.49M–
Q1 FY2020Mar 31, 2020$10.82M–

More Liquidia figures

See a number that looks wrong?